Table 5 Poisson regression of risk factors for mortality among patients receiving ART

Age (for each year increase)

1.04 (1.02-1.06)

<0.001

1.04 (1.02-1.06)

<0.001

Gender

Female

1.0

<0.001

1.0

0.002

Male

1.69 (1.25-2.29)

1.79 (1.21-2.66)

WHO stage at baseline

1/2

1.00

<0.001

1.0

0.011

3/4

3.34 (1.93-5.78)

2.06 (1.12-3.78)

Baseline anaemia severity

None

1.0

0.025

Mild

1.10 (0.67-1.80)

Moderate

1.66 (1.09-2.53)

Severe

2.28 (1.08-4.85)

Baseline CD4 category (cells/μL)

≥150

1.0

0.011

100-149

1.05 (0.66-1.67)

50-99

1.20 (0.77-1.86)

<50

1.83 (1.22-2.75)

Baseline viral load (cells/mL)

<5.0

1.0

0.007

≥5.0

1.51 (1.12-2.05)

CD4 category (cells/μL) (updated)**

≥500

1.0

<0.001

1.0

<0.001

200-499

2.05 (1.11-3.78)

1.38 (0.71-2.68)

100-199

6.39 (3.44-11.88)

2.75 (1.28-5.89)

<100

27.98 (15.59-50.22)

6.50 (2.82-15.00)

Viral load (cells/mL) (updated)**

<1,000

1.0

<0.001

1.0

0.034

≥1,000

6.91 (5.18-9.22)

1.62 (1.04-2.53)

WHO anaemia severity (updated)**

None

1.0

<0.001

1.0

<0.001

Mild

3.19 (2.11-4.81)

2.42 (1.55-3.77)

Moderate

10.89 (7.57-15.64)

6.03 (3.93-9.24)

Severe

25.94 (13.90-48.40)

7.99 (3.89-16.44)

Duration of ART (months)**

<4

1.0

<0.001

1.0

0.843

4-12

0.35 (0.24-0.52)

1.30 (0.77-2.16)

12-24

0.15 (0.10-0.24)

1.07 (0.55-2.07)

24-36

0.13 (0.08-0.21)

0.96 (0.46-1.99)

36-48

0.13 (0.08-0.22)

1.07 (0.46-2.46)

48-60

0.09 (0.05-0.17)

0.83 (0.32-2.17)

>60

0.08 (0.04-0.17)

0.78 (0.27-2.23)

Current AZT use

No

1.0

<0.001

1.0

0.501

Yes

0.38 (0.27-0.54)

0.86 (0.56-1.33)

Prevalent TB

No

1.0

<0.001

1.0

0.024

Yes

1.72 (1.27-2.33)

1.50 (1.06-2.14)

Incident TB

No

1.0

<0.001

1.0

<0.001

Yes

1.85 (1.34-2.55)

2.23 (1.47-3.37)